In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Denali Therapeutics Inc.

http://www.denalitherapeutics.com

Latest From Denali Therapeutics Inc.

Finance Watch: Neuron23 Adds $100m To Take First Drug Into The Clinic

Private Company Edition: Westlake Village BioPartners-founded Neuron23 will take the LRRK2 inhibitor NEU-723 for Parkinson’s disease into human testing before the end of 2022. Also, Celsius raised $83m in fresh VC cash and ITM added another €33m to its recent €25m equity financing.

StartUps and SMEs Financing

A Biopharma M&A Bonanza In 2022? Analysts Pick Top Targets And Likely Buyers

As big pharma company cash piles grow and biotech share prices plummet, a resurgence in mergers and acquisitions looks imminent.

M & A Companies

ABL’s Bispecific Antibody For Parkinson's Lands In Sanofi’s Hands

ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.

Deals Neurology

GSK-Partnered Alector Hit By Renewed Dementia Skepticism

Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker  neurofilament light chain.

BioPharmaceutical Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • F-star Gamma
    • Incro Pharmaceuticals
UsernamePublicRestriction

Register